enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Growth in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 7,800 shares, a growth of 7,700.0% from the August 31st total of 100 shares. Based on an average trading volume of 5,500 shares, the days-to-cover ratio is presently 1.4 days.

enGene Price Performance

Shares of ENGNW stock opened at $2.10 on Wednesday. enGene has a fifty-two week low of $0.39 and a fifty-two week high of $6.50. The stock’s 50-day moving average is $1.15 and its two-hundred day moving average is $2.55.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.